Navigation Links
TPI to Host Second Quarter of Fiscal Year 2013 Earnings Conference Call on Thursday, February 14, 2013 at 8:30 a.m. ET
Date:1/31/2013

CHENGDU, China, Jan. 31, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the second quarter of fiscal year 2013 ending December 31, 2012 to be held at 8:30 a.m. ET on Thursday, February 14, 2013.

Interested parties may access the call by dialing Toll free:

1-877-941-2068International: 

1-480-629-9712The conference ID is 4594892. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling

Toll free:

1-877-870-5176International: 

1-858-384-5517 From: 

02/14/13 @ 11:30 am ETTo:02/28/13 @ 11:59 pm ETReplay Pin Number:  

4594892This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=103373

About TPIHeadquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list (EDL) of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit:  http://www.tianyinpharma.com

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com , or email: ir@tpi.asia

 Tel:
+86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011 (China)

Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
2. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
3. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
4. The Female Health Company Reports Second Quarter Operating Results
5. Winner Medical Group Inc. to Host Second Quarter 2012 Earning Conference Call on Thursday, May 10, 2012 at 9:00 p.m. EDT
6. Biodel to Report Second Quarter Fiscal Year 2012 Financial Results on May 10, 2012
7. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
8. Elsevier Launches Second Annual Mosbys Superheroes of Nursing Contest During Nurses Week 2012
9. BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti
10. HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs Second Generation HIV Vaccine
11. Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Mass. , March 22, 2017  Applied ... mechanistic modeling to drug research and development, today ... Day 2017.  QSP Day 2017 is a day ... the quantitative systems pharmacology (QSP) community. The focus ... modeling is de-risking and accelerating drug research and ...
(Date:3/22/2017)... March 22, 2017 Hologic, Inc. (Nasdaq: ... the acquisition of Cynosure, Inc., a leader in medical ... cash. "We are pleased to complete our ... Michael Davin and the entire Cynosure team ... growing medical aesthetics market," said Steve MacMillan , ...
(Date:3/22/2017)... YORK , March 22, 2017 ... (EP) market is growing rapidly due to the significant ... report published by Allied Market Research, the global electrophysiology ... expected to reach $8.271 billion by 2022, with a ... and is used to diagnose abnormal heartbeats or arrhythmia. ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... The Rett ... a devastating neurological disorder that afflicts 350,000 individuals worldwide. Rett Syndrome is ... and almost exclusively strikes females. Following a normal infancy, Rett Syndrome takes ...
(Date:3/22/2017)... ... 22, 2017 , ... Last year, 43 million gallons of surplus milk was ... While excess dairy can be caused by several factors, one pharmaceutical company CEO ... to properly digest lactose, a sugar found in milk and milk products. ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... related services to communities across eastern Texas, is announcing a charity drive in ... to hungry children and adults. , Consistently a top-rated nonprofit organization for ...
(Date:3/22/2017)... Hilliard, OH (PRWEB) , ... March 22, 2017 ... ... that provides asset protection services and financial planning assistance to communities throughout central ... with Traumatic Brain Injuries. , Estimates from the Department of Defense and the ...
(Date:3/22/2017)... ... ... NYC Chiropractor Dr. Steven Shoshany recently helped host a seminar at his ... U.S. and focused on a new protocol for treating pain. Dr. Shoshany is among ... and furthermore the first seminar in the country was hosted at his Integrated Chiropractic ...
Breaking Medicine News(10 mins):